A Phase 2 interventional study of AM 5 + DM 0 and AM 5 + DM 2.5 in Hypertension, sponsored by TSH Biopharm Corporation Limited. Completed at 8 sites in Taiwan. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-11-13.
Sponsored by TSH Biopharm Corporation Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 116 studies in Hypertension with a site in Taiwan — 17 open to participants now, 20 under way, 5 of them phase 3. Hypertension · Taiwan.
Among the 116 studies in Hypertension with a site in Taiwan, this one is the 60th largest by enrollment of the 90 interventional ones that give a count, is one of 6 that started in 2012, is one of 12 in phase 2, and was the 49th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →17 of the 116 studies in Hypertension with a site in Taiwan are open now. Recruiting first, the newest first:
Fu Jen Catholic University · Sites in Taiwan
Ages 18+
Chang Gung University of Science and Technology · Sites in Taiwan
Ages 50+
Kaohsiung Armed Forces General Hospital · Sites in Taiwan
Ages 18–65
New Taipei City Medical Association · Sites in Taiwan
Medtronic Vascular · Sites in Taiwan, Australia, Belgium and 6 more countries
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 50 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
116 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 13 · Phase 3 27 · Phase 4 20
First in 2001; this study’s year is marked. 6 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 111 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 233 across the 90 interventional studies, 223 across the 24 observational. Of the 76 that completed or were terminated, 24 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
55 of 116 have an industry lead sponsor. The 10 most frequent:
TSH Biopharm Corporation Limited is the lead sponsor of 9 studies on the registry; none are open to participants now.
TSH Biopharm Corporation Limited has 3 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
7 of the studies in Hypertension with a site in Taiwan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT07222917AstraZenecaA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. | 2026-12-10 |
| NCT07578090Fu Jen Catholic UniversityRegional Innovation in Chronic Disease and Elderly Care | 2026-12-31 |
| NCT07603583Kaohsiung Armed Forces General HospitalAssessment of Heart Rate Variability for Predicting Obstructive Sleep Apnea in Patients With Hypertension | 2026-12-31 |
| NCT06819241Taichung Veterans General HospitalSelf-Management of Blood Pressure in Resistant Hypertension | 2027-04-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 116 studies in Hypertension with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the different dose of DMTA07 (DM) combine with amlodipine in the treatment of mild to moderate essential hypertension, and to define the optimized dose of DM in the combination therapy.
To compare the different dose of DM combine with amlodipine in the treatment of mild to moderate essential hypertension, and to define the optimized dose of DM in the combination therapy.
The purpose of this study is to compare the antihypertensive efficacy and tolerability of different dose of DM combines with amlodipine treatment, further to explore the optimized combination dose of DM.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient with mild to moderate essential hypertension at enrollment, which defined as the following:
Patient must have mean sitting SBP ≥140 and \<180 mmHg or mean sitting DBP ≥90 and \<110 mmHg at enrollment;
Exclusion Criteria:
Hepatic or renal dysfunction as defined by the following parameters:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Amlodipine 5 mg + DMTA07 0mg, once daily
Drug: AM 5 + DM 0
Amlodipine 5 mg + DMTA07 2.5mg, once daily
Drug: AM 5 + DM 0 · Drug: AM 5 + DM 2.5
Amlodipine 5 mg + DMTA07 7.5mg, once daily
Drug: AM 5 + DM 0 · Drug: AM 5 + DM 2.5 · Drug: AM 5 + DM 7.5
Amlodipine 5 mg + DMTA07 30mg, once daily
Drug: AM 5 + DM 0 · Drug: AM 5 + DM 2.5 · Drug: AM 5 + DM 7.5 · Drug: AM 5 + DM 30
Amlodipine 5 mg + DMTA07 0mg, once daily
Also known as: Amlodipine (AM), DMTA07 (DM)
Amlodipine 5 mg + DMTA07 2.5mg, once daily
Also known as: Amlodipine (AM), DMTA07 (DM)
Amlodipine 5 mg + DMTA07 7.5mg, once daily
Also known as: Amlodipine (AM), DMTA07 (DM)
Amlodipine 5 mg + DMTA07 30mg, once daily
Also known as: Amlodipine (AM), DMTA07 (DM)
*SBP reduction=SBP each visit- SBPvisit2
The primary objective of this study is to compare the sitting systolic blood pressure (mmHg) reduction\* between four dose regimens, the baseline is defined as the actual SBP value after 2 weeks of amlodipine run-in period
Time frame: 14 weeks
The secondary objectives of the study include: Efficacy/Safety
Efficacy: To compare the sitting diastolic blood pressure (mmHg) reduction\* between four dose regimens, the baseline is defined as the actual DBP value after 2 weeks of amlodipine run-in period To evaluate the percentage of SBP reduction in four treatment regimens To evaluate the changes of blood pressure (mmHg) in different clusters; such as diabetes etc. Safety: To evaluate the pulse rate changes To evaluate incidences of adverse events To evaluate the change of laboratory test results from baseline
Time frame: 14 weeks
The record gives a start of Jul 2012, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
TSH Biopharm Corporation Limited